Biotransformation of the platinum drug JM216 following oral administration to cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 2, 1996, Pages 155-162

  Raynaud, F I ^a   Mistry, P ^a,c   Donaghue, A ^a   Poon, G K ^a   Kelland, L R ^a   Barnard, C F J ^b   Murrer, B A ^b   Harrap, K R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

human plasma ultrafiltrates; JM216; metabolism; platinum complexes

Indexed keywords

CISPLATIN; DRUG METABOLITE; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM DERIVATIVE; SATRAPLATIN;

ARTICLE; BIOTRANSFORMATION; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CELL DEATH; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM; TUMOR CELLS, CULTURED;

EID: 0029947258     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050464     Document Type: Article

References (27)

1. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR (1990) Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 [Suppl A]: 51-57
2. Calvert H, Judson IR, Van der Vight WJF (1993) Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. In: Workman P, Graham MA (eds) Cancer surveys, vol 17. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 189-217
3. Daley-Yates PT, McBrien DCH (1983) Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo. Biochem Pharmacol 32: 181-184
4. Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33: 3036-3070
5. Daley-Yates PT, McBrien DCH (1985) The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Biochem Pharmacol 34: 1423-1428.
6. Abrams MJ, Giandomenico CM, Murrer BA, Vollano JF (1989) European Patent 328274. European Patent Office, The Hague
7. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Barnard CFJ, Harrap KR, Goddard PM, Kelland LR, Morgan SE (1991) Synthesis and reactions of a new class of orally active Pt (IV) antitumour complexes. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum, New York, pp 93-100
8. Gibbons GR, Wrick S, Chaney SG (1989) Rapid reduction of tetrachloro(D,L,-trans)1,2-diaminocycloplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res. 49: 1402-1407
9. Horwitch A (1989) Germ cell tumour chemotherapy. Br J Cancer 59: 156-165
10. Kelland LR, Clarke SJ, McKeage MJ (1992) Advances in platinum cancer chemotherapy. Platinum Met Rev 36: 178-184
11. Kelland LR, Murrer BA, Abel G, Harrap KR (1991) Structure -activity relationship in a series of novel platinum(II) and platinum(IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J Cell Pharmacol 2: 331-342
12. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitimor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53: 2581-2586
13. Lim MC, Martin RB (1976) The nature and activity of Pt(II) complexes in aqueous solutions J Inorg Nucl Chem 38: 1911-1915
14. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109-1115
15. McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR (1993) Lack of nephrotoxicity of oral ammine/ amine platinum(IV) dicarboxylate complexes in rodents. Br J Cancer 67: 996-1000
16. McKeage MJ, Raynaud FI, Ward J, Berry C, Odell D, Mistry P, Kelland LR, Santabarbara P, Harrap KR, Judson IR (1994) Phase I study of orally administered platinum complex (JM216) using a daily x 5 administration schedule. Proc Am Soc Clin Oncol 3: A337
17. McKeage MJ, Boxall FE, Jones M, Harrap KR (1994) Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54: 629-631
18. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neil C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR, Judson IR (1995) Phase I and pharmacological study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451-458
19. Mistry P, Lee C, McBrien DCH (1989) Intracellular metabolites of cisplatin in the rat kidney. Cancer Chemother Pharmacol 24: 73-79
20. 2 divided over three consecutive days. Br J Cancer 61: 460-464
21. Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11: 251-263
22. Peckham MJ, Horwich A, Brada M, Drury A, Hendry WF (1991) cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ cell tumors: a preliminary report. Cancer Treat Rev 12 [Suppl A]:101-110
23. Pendyala L, Craven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970-5986
24. Pendyala L, Cowens JW, Chheda GB, Dutta SP, Creaven PG (1988) Identification of cis-Dichloro-bis-isopropylamine-platinum(II) as a metabolite of iproplatin in humans. Cancer Res. 48: 3533-3536
25. Pendyala L, Walsh JR, Huq MM, Arakali AV, Cowens JW, Creaven PJ (1989) Uptake and metabolism of iproplatin in murine L1210 cells. Cancer Chemother Pharmacol 25: 15-18
26. Poon GK, Mistry P, Raynaud F, Harrap KR, Murrer BA, Barnard C, Pesch R, Muenster H (1995) Metabolic studies of platinum anticancer drug JM216 in human plasma ultrafiltrates using LC/ESI/MS on a magnetic sector mass spectrometer. Proc Am Soc Mass Spectrom 42 (in press)
27. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303-2316